Viewing nowCombinationOlostan Tablet 40/10 mg (Olmesartan Medoxomil, Rosuvastatin)
Rosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 201604125 · Approved 2016.06.30 · Insurance code 641606230
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk
This medication is used for patients requiring co-administration of the two ingredients, Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is used to treat essential hypertension and effectively controls blood pressure. Rosuvastatin is utilized as an adjunct for various dyslipidemic conditions that are difficult to manage through diet and exercise. It also helps to slow the progression of atherosclerosis and reduce the risk of stroke, myocardial infarction, and revascularization procedures in patients with cardiovascular disease risk factors. Therefore, this medication is used to manage both hypertension and hyperlipidemia, as well as to reduce cardiovascular disease risk.
This medicine is for use only in adults. The dosage should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that this medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have intravascular volume depletion (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a lower dose while closely monitoring their condition. 2. Older adults No dosage adjustment is necessary when this medicine is administered to older adults aged 65 years or older. Although no overall differences in efficacy or safety have been observed between older and younger patients, increased sensitivity in some older patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to the maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is necessary. 3. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment Although systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, it was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
The safety and efficacy of this medicine in children under 18 years of age have not been established.
This medication can cause serious harm or death to the fetus and newborn if administered to women in the second or third trimester of pregnancy; therefore, it should be discontinued immediately once pregnancy is confirmed. It should not be used by patients allergic to any ingredients in this medication or to the medication itself, women who are pregnant or may become pregnant, breastfeeding women, patients with severely impaired kidney function, or patients with severe liver disease. Caution is needed in patients with reduced blood volume or sodium, as blood pressure may drop too low during the initial administration of this medication, and immediate action should be taken if symptoms of hypotension occur. Patients with compromised kidney function, kidney transplant recipients, patients with renal artery stenosis, and those at risk for hyperkalemia should have their kidney function and serum potassium levels monitored periodically before and during treatment. There may be muscle-related side effects, so any symptoms such as muscle pain, weakness, or cramps should be reported to a healthcare professional immediately, especially when taking high doses. This medication may affect liver function; therefore, patients with a history of liver disease should have their liver function tested regularly before and during treatment. During treatment, it is advisable to avoid or minimize alcohol consumption, especially in patients with a history of liver disease. When taken with other antihypertensive agents, blood pressure may become too low, so blood pressure should be monitored frequently, and dosage adjustments may be necessary. This medication can interact with certain drugs, so patients taking other medications should inform their healthcare provider, particularly concerning the co-administration of potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, and fibrate-class medications. Women of childbearing potential should use appropriate contraception, and this medication should not be used during pregnancy or breastfeeding. The safety and efficacy in pediatric patients under 18 years have not been established, so it is advisable not to use this medication in children. Elderly patients may experience increased body concentrations of this medication, necessitating dosage adjustment and caution during administration. Overdose may lead to symptoms such as hypotension and palpitations; in such cases, patients should seek immediate medical attention for appropriate treatment. This medication should be kept out of reach of children and it is safer not to transfer it to another container. If severe skin rash, difficulty breathing, swelling of the face or neck occurs while taking this medication, discontinue use immediately and consult a healthcare professional.
Increased ALT, increased AST, elevated serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, cavities, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, dental extraction, thoracic pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption syndrome resembling intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, including orthostatic dizziness, palpitations, elevated blood pressure, low back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory tract infection, asthma, hypersensitivity reactions including angioedema, diabetes, pancreatitis, pruritus, rash and urticaria, myalgia, myopathy including myositis, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, both fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be kept in a tightly closed container. It is recommended to store it at room temperature between 1°C and 30°C.
Yellow, round, film-coated tablet
30 tablets (10 tablets/PTP) x 3, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Mothers Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.